Friday, June 19, 2026

pharma · Acute Myeloid Leukemia · Breast Cancer

First People's Hospital

First People's Hospital clinical programs — 186 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

SAN DIEGO, CA, CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
SAN DIEGO, CA, CN
Programs
1136
Drugs
626
Patents
123
Intelligence · Clinical Programs

First People's Hospital projects

186 ClinicalTrials.gov programs sponsored by First People's Hospital.

First People's Hospital has 186 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

Page 1 of 4
  1. "Nefecon®","Ambrisentan"

    The First People's Hospital of Lianyungang

    IgA Nephropathy

    approved small molecule active

    1 trial
  2. 20mg Febuxostat

    The First People's Hospital of Lianyungang

    Hyperuricemia

    approved small molecule active

    1 trial
  3. 37.5mg Pregabalin + 75mg Pregabalin

    The First People's Hospital of Lianyungang

    Pain, Postoperative

    approved small molecule completed

    1 trial
  4. ALA

    The First People's Hospital of Lianyungang

    Actinic Keratoses

    approved small molecule active

    1 trial
  5. AN69ST hemofilter

    The First People's Hospital of Lianyungang

    Critical Ill Patients

    approved other completed

    1 trial
  6. Aerosolized 13 cis retinoic acid plus Vitamin D

    The First People's Hospital of Lianyungang

    Post COVID-19 Anosmia (Loss of Smell)

    approved small molecule active

    1 trial
  7. Alprostadil

    The First People's Hospital of Lianyungang

    Stroke

    approved small molecule active

    1 trial
  8. Amlodipine besylate

    The First People's Hospital of Lianyungang

    Hypertension

    approved small molecule active

    1 trial
  9. Anti-peristaltic ileosigmoid anastomosis

    The First People's Hospital of Lianyungang

    Constipation

    approved other completed

    1 trial
  10. Aspirin

    The First People's Hospital of Lianyungang

    Recurrent Pregnancy Loss

    approved small molecule active

    1 trial
  11. Aspirin

    The First People's Hospital of Lianyungang

    G6PD Deficiency

    approved small molecule active

    1 trial
  12. Azvudine

    The First People's Hospital of Lianyungang

    COVID-19

    approved small molecule active

    1 trial
  13. Babaodan oral capsule

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    approved small molecule active

    1 trial
  14. Basiliximab

    The First People's Hospital of Lianyungang

    Safety and Efficacy

    approved small molecule active

    1 trial
  15. Basiliximab,

    The First People's Hospital of Lianyungang

    Beta-Thalassemia Major

    approved small molecule completed

    1 trial
  16. Berberine

    The First People's Hospital of Lianyungang

    Diabetes Mellitus

    approved small molecule completed

    1 trial
  17. Blinatumomab

    The First People's Hospital of Lianyungang

    Acute B-cell Lymphoblastic Leukemia

    approved small molecule active

    1 trial
  18. Budesonide 200 microgram/Puff, HFA MDI

    The First People's Hospital of Lianyungang

    Asthma

    approved small molecule completed

    1 trial
  19. Bupivacaine Hydrochloride

    The First People's Hospital of Lianyungang

    Pulmonary Nodule

    approved small molecule active

    1 trial
  20. Busulfan

    The First People's Hospital of Lianyungang

    Thalassemia Major

    approved small molecule completed

    1 trial
  21. Butylphthalide

    The First People's Hospital of Lianyungang

    Focal Epilepsy

    approved small molecule active

    1 trial
  22. CFNB group

    The First People's Hospital of Lianyungang

    Postoperative Pain

    approved other active

    1 trial
  23. CSII

    The First People's Hospital of Lianyungang

    Diabetes Mellitus, Type 2

    approved small molecule completed

    1 trial
  24. CTB group

    The First People's Hospital of Lianyungang

    Post-operative Pain

    approved other active

    1 trial
  25. Calcitriol

    The First People's Hospital of Lianyungang

    Glomerulonephritis

    approved small molecule active

    1 trial
  26. Chemoembolization and Response-Dependent Resection

    The First People's Hospital of Lianyungang

    Resectable Hepatocellular Carcinoma Beyond Milan Criteria

    approved other active

    1 trial
  27. Cholecalciferol

    The First People's Hospital of Lianyungang

    Peritoneal Dialysis-associated Peritonitis

    approved small molecule active

    1 trial
  28. Cilostazol

    The First People's Hospital of Lianyungang

    Cerebral Small Vessel Disease

    approved small molecule active

    1 trial
  29. Cinobufacini injection

    The First People's Hospital of Lianyungang

    Liver Cancer

    approved small molecule active

    1 trial
  30. Ciprofol

    The First People's Hospital of Lianyungang

    ECMO Treatment

    approved small molecule active

    1 trial
  31. Ciprofol

    The First People's Hospital of Lianyungang

    Postoperative Delirium (POD)

    approved small molecule active

    1 trial
  32. Combination of antiplatelet drugs and anticoagulants for at least one month

    The First People's Hospital of Lianyungang

    Acute Myocardial Infarction

    approved small molecule active

    1 trial
  33. Dabigatran Etexilate

    The First People's Hospital of Lianyungang

    Atrial Fibrillation

    approved small molecule active

    1 trial
  34. Dapagliflozin 10 MG

    The First People's Hospital of Lianyungang

    Type 2 Diabetes Mellitus

    approved small molecule active

    1 trial
  35. Daphnetin

    The First People's Hospital of Lianyungang

    Lower Extremity Lymphedema

    approved small molecule active

    1 trial
  36. Dental foam "Biorepair PERIBIOMA"

    The First People's Hospital of Lianyungang

    Oral Health

    approved small molecule completed

    1 trial
  37. Desmopressin

    The First People's Hospital of Lianyungang

    Patients Undergoing Endoscopic Sinus Surgery

    approved small molecule completed

    1 trial
  38. Dex-Esk

    The First People's Hospital of Lianyungang

    Older Patients

    approved small molecule active

    1 trial
  39. Dexamethasone

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    approved small molecule active

    1 trial
  40. Dexamethasone

    The First People's Hospital of Lianyungang

    Carcinoma, Non-Small-Cell Lung

    approved small molecule terminated

    1 trial
  41. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Elderly

    approved small molecule completed

    3 trials
  42. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Older Patients

    approved small molecule active

    1 trial
  43. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Overall Survival

    approved small molecule completed

    1 trial
  44. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Obstructive Sleep Apnea

    approved small molecule completed

    1 trial
  45. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Postoperative Delirium After Living Donor Renal Transplantation

    approved small molecule active

    1 trial
  46. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Breast Cancer

    approved small molecule completed

    1 trial
  47. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Renal Function

    approved small molecule active

    1 trial
  48. Dexmedetomidine-esketamine combination

    The First People's Hospital of Lianyungang

    Obstructive Sleep Apnea

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does First People's Hospital have?

186 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.